The combined targeting of USP1 and MAST1 by pimozide and lestaurtinib synergistically enhanced cisplatin sensitivity in the mouse xenografts, significantly reducing tumor volume and weight compared with a single treatment of pimozide or lestaurtinib (Figure 8I, J). The gene discussed is USP1; the disease is neoplasm.